" class="no-js "lang="en-US"> TILT Biotherapeutics Announces Close of €22 Million Financing
Saturday, April 01, 2023

TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials

TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million financing round. This follows on from the first close of EUR 10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance to Phase II the company’s combination trials which use oncolytic immunotherapies synergistically with checkpoint inhibitors.

This final close of €12 million includes €5.9 million equity from the European Innovation Council (EIC) Fund as well as a €2.1 million grant from EIC’s Accelerator programme, as well as investments from Stephen Industries Inc Oy and ACME Investments SPF Sàrl. The EIC Fund is TILT’s first significant international investor. The EIC investment decision followed a due diligence process by the European Investment Bank, which supports the EIC Fund as Investment Advisor.

TILT Biotherapeutics’ founder and CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients with oncolytic viruses, said, “We’re pleased to have achieved this round of €22 million to advance our promising pipeline of armed oncolytic viruses. Our trials are progressing well through Phase I, and this new funding will support us in progressing them into Phase II, another key step for these new therapies to reach patients in a range of cancers”.

Timo Ahopelto, Founding Partner of Lifeline Ventures, said, “We invest in future category-leading companies with strong founders, and support them through their growth. We saw the potential in TILT’s cancer immunotherapies early on and continue to build on that potential in Europe as well as the U.S market with this funding round.”

Hermann Hauser, member of the EIC Fund Board said, “Combining grants and equity is unique to the European Innovation Council. It bridges the funding gap for highly innovative companies, unlocks additional private investments and enables them to scale up in Europe.”

The heart of TILT’s innovative approach revolves around the use of armed oncolytic adenoviruses, using cytokines and other molecules to boost the patient’s immune response to better enable it to find and destroy cancer cells. The company is advancing its pipeline of programs including its lead asset TILT-123, in further clinical trials, including in combination with immune checkpoint inhibitors.

  1. Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
  2. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
  3. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  4. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  5. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more